New anti-idiotypic Affimer binders to trastuzumab


Anti-idiotypic reagents must be highly specific, sensitive and reproducible. Affimer technology meets these requirements for critical reagents in pharmacokinetic assays. Our new study highlights the development and validation of trastuzumab specific anti-idiotypic Affimer binders within a pharmacokinetic assay, showing that:

  • Affimer binders to trastuzumab were identified and validated within just 3 months.
  • The selected Affimer binder was entirely specific for the trastuzumab antibody target and showed comparable sensitivity to the natural ligand, HER2.
  • A high level of batch-to-batch reproducibility was observed across four separate batches of Affimer protein.

*By registering your email you agree to receive further updates from Avacta Life Sciences about our products and services which are specific to your areas of interest.